Picoplatin
 | |
| Names | |
|---|---|
| IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride | |
| Identifiers | |
181630-15-9  | |
| ChemSpider | 154428  |
| |
| Jmol-3D images | Image |
| PubChem | 177358 |
| |
| Properties | |
| Molecular formula |
C6H10Cl2N2Pt |
| Molar mass | 376.15 g·mol−1 |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| verify (what is: /?) | |
| Infobox references | |
Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.[1]
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer.[4]
References
- ↑ The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Transactions
- ↑ Picoplatin Clinical Results, Poniard Pharmaceuticals
- ↑ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
- ↑ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009
| ||||||||||||||||||||||||||||